Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupal Patel

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymeraseFrank Ruebsam, Zhongxiang Sun, Benjamin K Ayida, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazineYuefen Zhou, Stephen E Webber, Douglas E Murphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on EnzalutamideWassim Abida, Andrew W Hahn, Neal Shore, et al.
Bioorganic & Medicinal Chemistry Letters|April 30, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK propertiesMaria V Sergeeva, Yuefen Zhou, Darian M Bartkowski, et al.
Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2008
Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymeraseFrank Ruebsam, Stephen E Webber, Martin T Tran, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessmentsLian-Sheng Li, Yuefen Zhou, Douglas E Murphy, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2008
Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymeraseSun Hee Kim, Martin T Tran, Frank Ruebsam, et al.
Bioorganic & Medicinal Chemistry Letters|July 30, 2008
4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Stephen E Webber, et al.
Cancer Research|November 6, 2025
Enozertinib is a Selective, Brain-penetrant EGFR inhibitor for Treating Non-small Cell Lung Cancers with EGFR Exon 20 and Atypical MutationsMelissa R Junttila, Claire E Repellin, Sumeet Salaniwal, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymeraseFrank Ruebsam, Zhongxiang Sun, Benjamin K Ayida, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazineYuefen Zhou, Stephen E Webber, Douglas E Murphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on EnzalutamideWassim Abida, Andrew W Hahn, Neal Shore, et al.
Bioorganic & Medicinal Chemistry Letters|April 30, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK propertiesMaria V Sergeeva, Yuefen Zhou, Darian M Bartkowski, et al.
Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2008
Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymeraseFrank Ruebsam, Stephen E Webber, Martin T Tran, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessmentsLian-Sheng Li, Yuefen Zhou, Douglas E Murphy, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2008
Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymeraseSun Hee Kim, Martin T Tran, Frank Ruebsam, et al.
Bioorganic & Medicinal Chemistry Letters|July 30, 2008
4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Stephen E Webber, et al.
Cancer Research|November 6, 2025
Enozertinib is a Selective, Brain-penetrant EGFR inhibitor for Treating Non-small Cell Lung Cancers with EGFR Exon 20 and Atypical MutationsMelissa R Junttila, Claire E Repellin, Sumeet Salaniwal, et al.
Pageof 9